LB Pharmaceuticals, Inc.(LBRX)
$40.30-2.69 (-6.26%)
LBRX
LB Pharmaceuticals, Inc. financials statements
$40.30
At close:-2.69 (-6.26%)
Want to see LBRX full AI Analyst Report?
LB Pharmaceuticals, Inc. (LBRX) Ratios
52 Followers
LB Pharmaceuticals, Inc. Ratios
LBRX's free cash flow for Q3 2026 was $-64.36M. For the 2026 fiscal year, LBRX's free cash flow was decreased by $-70.00K and operating cash flow was $-64.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 41.44 | 3.56 | 17.51 | 45.82 |
| Quick Ratio | 41.44 | 3.56 | 17.51 | 45.82 |
| Cash Ratio | 33.62 | 2.83 | 5.75 | 45.64 |
| Solvency Ratio | -2.14 | -0.49 | -0.08 | -0.29 |
| Operating Cash Flow Ratio | -4.73 | -6.54 | -4.64 | -5.82 |
| Short-Term Operating Cash Flow Coverage | -48.23 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 296.81M | $ -99.21M | $ -34.50M | $ -28.82M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.01 | 0.11 | 0.00 | 1.12 |
| Debt-to-Equity Ratio | 0.01 | -0.04 | 0.00 | -0.84 |
| Debt-to-Capital Ratio | 0.01 | -0.04 | 0.00 | -5.18 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -5.18 |
| Financial Leverage Ratio | 1.04 | -0.35 | -1.32 | -0.75 |
| Debt Service Coverage Ratio | -34.09 | 0.00 | -0.30 | -5.67 |
| Interest Coverage Ratio | 0.00 | 0.00 | -2.36 | -1.31 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.39 |
| Interest Debt Per Share | 0.14 | 1.05 | 1.36 | 7.43 |
| Net Debt to EBITDA | 9.91 | 0.31 | 10.37 | -0.23 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.02% | 100.01% |
| EBT Per EBIT | 82.90% | 97.33% | 55.15% | 510.75% |
| Return on Assets (ROA) | -8.05% | -188.17% | -13.74% | -66.76% |
| Return on Equity (ROE) | -8.37% | 66.74% | 18.20% | 49.80% |
| Return on Capital Employed (ROCE) | -9.95% | -254.99% | -26.42% | -13.36% |
| Return on Invested Capital (ROIC) | -9.93% | -250.19% | -26.42% | -13.36% |
| Return on Tangible Assets | -8.05% | -188.17% | -13.74% | -66.76% |
| Earnings Yield | -4.48% | -103.05% | -10.24% | -23.42% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -1.39 | -14.99 | -3.42 | -0.77 |
| Free Cash Flow Per Share | -1.39 | -15.21 | -3.42 | -0.77 |
| Dividend Paid and CapEx Coverage Ratio | -677.08 | -68.99 | -483.76 | 0.00 |
| Capital Expenditure Coverage Ratio | -677.08 | -68.99 | -483.76 | 0.00 |
| Operating Cash Flow Coverage Ratio | -9.86 | -14.33 | 0.00 | -0.11 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.26% | -87.89% | -19.78% | -4.45% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -22.26 | -0.97 | -9.76 | -4.27 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.87 | -0.65 | -1.78 | -2.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.97 | -1.14 | -5.05 | -22.45 |
| Price-to-Operating Cash Flow Ratio | -16.00 | -1.15 | -5.06 | -22.45 |
| Price-to-Earnings Growth (PEG) Ratio | 0.24 | -0.00 | 0.17 | 0.00 |
| Enterprise Value Multiple | -12.72 | -0.67 | -32.02 | -5.25 |
| Enterprise Value | 316.56M | 41.96M | 46.28M | 64.00M |
| EV to EBITDA | -12.72 | -0.67 | -32.02 | -5.25 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -8.98 | -0.78 | -3.82 | -23.46 |
| EV to Operating Cash Flow | -8.99 | -0.79 | -3.83 | -23.46 |
| Tangible Book Value Per Share | 11.91 | -26.71 | -9.74 | -8.14 |
| Shareholders’ Equity Per Share | 11.91 | -26.71 | -9.74 | -8.14 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.00 | -17.83 | -1.77 | -4.05 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 4.33 | 1.18 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.40 | 0.84 | 1.93 | 0.19 |
Currency in USD

